Colorectal cancer (CRC) is expected to contribute to a burden of 3.2 million new cases and 1.6 million deaths by 2040. The authors open by discussing how microbes can be used to prevent CRC. Probiotics, when administered appropriately, enhance the intestinal barrier, modulate the hosts' immune response, remodel the gut microbial composition, and even induce targeted cancer cell death. The first-generation probiotics were formulations of lactic acid bacteria (LBA) from Lactobacillus, Lactococcus, Streptococcus, Enterococcus, Bacillus, Saccharomyces, and Bifidobacterium genera. On the other hand, next-generation probiotics (NGPs) incorporate microbes such as Bacteroides fragilis, Clostridium butyricum, Akkermansia muciniphila, and Faecalibacterium prausnitzii. Next,...